A new content agreement brings peer-reviewed research from more than 300 Sage journals into OpenEvidence, with direct citations back to the original articles

Sage, an independent academic publisher of peer-reviewed research across the health, medical, and social sciences, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a strategic partnership to bring Sage's peer-reviewed content into OpenEvidence. Under the agreement, clinicians using OpenEvidence at the point of care will be able to draw on evidence from over 300 Sage journals spanning the life and biomedical sciences, health sciences, medicine, and nursing, with direct citations back to the original articles.

The volume of published medical research now far outpaces what any individual clinician can track. Studies routinely take years to move from publication into everyday practice, and much of the gap is a retrieval problem: the evidence exists, but not in a form a clinician can surface in the ninety seconds between patients. The partnership is designed to shorten that path for Sage's research.

Adding Sage’s portfolio expands the range of specialty literature OpenEvidence can surface and synthesize when physicians ask clinical questions, deepening the evidence available across the platform. "Sage is committed to getting research into the hands of people who need it in the most useful and meaningful way,” said Bob Howard, Executive Vice President, Global Journals, at Sage. “With Sage content integrated into OpenEvidence’s platform, we can extend our reach and impact and meet doctors and clinicians where they are.”

Sage will license a portfolio of its scientific and medical content to OpenEvidence, including journals from key societies such as American Orthopaedic Society for Sports Medicine, World Stroke Organization, American Society of Neurorehabilitation, International Headache Society,

Australian Society of Anaesthetists, International Society for Cerebral Blood Flow & Metabolism, Association of Diabetes Care & Education Specialists and International Society of Endovascular Specialists.

OpenEvidence, now used by 60% of practicing U.S. physicians, gives Sage research a direct path into the clinical questions physicians are asking every day. Sage content will surface within OpenEvidence answers when clinically relevant, alongside the peer-reviewed literature already available on the platform, and every response that draws on it will cite and link back to the underlying article.

“We are delighted to work with Sage to bring the clinical content they publish to the point of care.” said Dr. Travis Zack, Chief Medical Officer at OpenEvidence, “Through Sage’s representation of outstanding medical societies, and the recent additions of IOS Press and Mary Ann Liebert, their clinical portfolio touches all areas of medicine. ”

---

About Sage

Sage is a global academic publisher of books, journals, and library resources with a growing range of technologies to enable discovery, access, and engagement. Believing that research and education are critical in shaping society, 24-year-old Sara Miller McCune founded Sage in 1965. Today, we are controlled by a group of trustees charged with maintaining our independence and mission indefinitely. For more information, visit sagepub.com.

About OpenEvidence

OpenEvidence is the most popular AI for doctors in the United States. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified U.S. healthcare professionals making high-stakes clinical decisions at the point of care, with evidence that is sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world's collective medical knowledge, OpenEvidence is now used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260929512232/en/